Development and validation of a cost-utility model for Type1 diabetes mellitus

被引:8
|
作者
Wolowacz, S. [1 ]
Pearson, I. [1 ]
Shannon, P. [2 ]
Chubb, B. [3 ]
Gundgaard, J. [4 ]
Davies, M. [5 ]
Briggs, A. [6 ]
机构
[1] RTI Hlth Solut, Hlth Econ, Manchester, Lancs, England
[2] RTI Hlth Solut, Patient Reported Outcomes, Manchester, Lancs, England
[3] Novo Nordisk Ltd, European Hlth Econ & Outcomes Res, Gatwick, W Sussex, England
[4] Novo Nordisk AS, Hlth Econ & HTA, Bagsvaerd, Denmark
[5] Univ Leicester, Diabet Res Ctr, Leicester, Leics, England
[6] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow, Lanark, Scotland
关键词
RISK-FACTORS; COMPLICATIONS; DISEASE; NEUROPATHY; EURODIAB; COHORT; ONSET;
D O I
10.1111/dme.12663
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AimsTo develop a health economic model to evaluate the cost-effectiveness of new interventions for Type1 diabetes mellitus by their effects on long-term complications (measured through mean HbA(1c)) while capturing the impact of treatment on hypoglycaemic events. MethodsThrough a systematic review, we identified complications associated with Type1 diabetes mellitus and data describing the long-term incidence of these complications. An individual patient simulation model was developed and included the following complications: cardiovascular disease, peripheral neuropathy, microalbuminuria, end-stage renal disease, proliferative retinopathy, ketoacidosis, cataract, hypoglycemia and adverse birth outcomes. Risk equations were developed from published cumulative incidence data and hazard ratios for the effect of HbA(1c), age and duration of diabetes. We validated the model by comparing model predictions with observed outcomes from studies used to build the model (internal validation) and from other published data (external validation). We performed illustrative analyses for typical patient cohorts and a hypothetical intervention. ResultsModel predictions were within 2% of expected values in the internal validation and within 8% of observed values in the external validation (percentages represent absolute differences in the cumulative incidence). ConclusionsThe model utilized high-quality, recent data specific to people with Type1 diabetes mellitus. In the model validation, results deviated less than 8% from expected values. What's new? A simple cost-utility model was developed to evaluate new interventions for Type1 diabetes mellitus by assessing the association between the interventions' effects on mean HbA(1c) and long-term complications and the risk of hypoglycaemic events. High-quality, recently reported data specific to people with Type1 diabetes mellitus were identified by a systematic review. Model validation included review by clinical and economic experts, verification of input data and formulae, and comparison of model predictions with observations from studies used to build the model and other published data.
引用
收藏
页码:1023 / 1035
页数:13
相关论文
共 50 条
  • [41] The development of a model for translation of the Neck Disability Index to utility scores for cost-utility analysis in cervical disorders
    Richardson, Shawn S.
    Berven, Sigurd
    SPINE JOURNAL, 2012, 12 (01): : 55 - 62
  • [42] Cost-utility analysis of second-line anti-diabetic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin
    Chien, Ching-Lun
    Chen, Yen-Chou
    Malone, Daniel C.
    Peng, Yueh-Lung
    Ko, Yu
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (10) : 1619 - 1626
  • [43] Fulminant type1 diabetes mellitus with anti-programmed cell death-1 therapy
    Okamoto, Masahide
    Okamoto, Mitsuhiro
    Gotoh, Koro
    Masaki, Takayuki
    Ozeki, Yoshinori
    Ando, Hisae
    Anai, Manabu
    Sato, Asami
    Yoshida, Yuichi
    Ueda, So
    Kakuma, Tetsuya
    Shibata, Hirotaka
    JOURNAL OF DIABETES INVESTIGATION, 2016, 7 (06) : 915 - 918
  • [44] Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus
    Hu, Shanshan
    Deng, Xun
    Ma, Yanjiao
    Li, Zhilei
    Wang, Yuhang
    Wang, Yong
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2021, 19 (01) : 69 - 79
  • [45] Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus
    Shanshan Hu
    Xun Deng
    Yanjiao Ma
    Zhilei Li
    Yuhang Wang
    Yong Wang
    Applied Health Economics and Health Policy, 2021, 19 : 69 - 79
  • [46] Development and validation of a cardiovascular risk prediction model in type 1 diabetes
    Stuart J. McGurnaghan
    Paul M. McKeigue
    Stephanie H. Read
    Stefan Franzen
    Ann-Marie Svensson
    Marco Colombo
    Shona Livingstone
    Bassam Farran
    Thomas M. Caparrotta
    Luke A. K. Blackbourn
    Joseph Mellor
    Ioanna Thoma
    Naveed Sattar
    Sarah H. Wild
    Soffia Gudbjörnsdottir
    Helen M. Colhoun
    Diabetologia, 2021, 64 : 2001 - 2011
  • [47] Development and validation of a cardiovascular risk prediction model in type 1 diabetes
    McGurnaghan, Stuart J.
    McKeigue, Paul M.
    Read, Stephanie H.
    Franzen, Stefan
    Svensson, Ann-Marie
    Colombo, Marco
    Livingstone, Shona
    Farran, Bassam
    Caparrotta, Thomas M.
    Blackbourn, Luke A. K.
    Mellor, Joseph
    Thoma, Ioanna
    Sattar, Naveed
    Wild, Sarah H.
    Gudbjornsdottir, Soffia
    Colhoun, Helen M.
    DIABETOLOGIA, 2021, 64 (09) : 2001 - 2011
  • [48] FALLS AND FRACTURES IN PATIENTS WITH TYPE1 DIABETES
    Sulaiman, Raashda A.
    Narendran, Parth
    Cooper, Mark
    Ayuk, John
    Hiwot, Tarekegn
    Gittoes, Neil
    OSTEOPOROSIS INTERNATIONAL, 2012, 23 : S599 - S599
  • [49] Development and Validation of a Chronic Kidney Disease Prediction Model for Type 2 Diabetes Mellitus in Thailand
    Tuntayothin, Wilailuck
    Kerr, Stephen John
    Boonyakrai, Chanchana
    Udomkarnjananun, Suwasin
    Chukaew, Sumitra
    Sakulbumrungsil, Rungpetch
    VALUE IN HEALTH REGIONAL ISSUES, 2021, 24 : 157 - 166
  • [50] Development and validation of a model that predicts the risk of diabetic retinopathy in type 2 diabetes mellitus patients
    Jing Yang
    Sheng Jiang
    Acta Diabetologica, 2023, 60 : 43 - 51